Association between polymorphisms of endothelial nitric oxide synthase gene (NOS3) and left posterior wall thickness (LPWT) of the heart in Fabry disease

Journal of Inherited Metabolic Disease

Volumn 31, Issue SUPPL. 2, 2008, Pages

  Rohard, I ^a,c   Schaefer, E ^a   Kampmann, C ^b   Beck, M ^b   Gal, A ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c Altonaer Kinderkrankenhaus   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NOS3 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHILD; ECHOGRAPHY; ENZYMOLOGY; EXON; FABRY DISEASE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GERMANY; HAPLOTYPE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INTRON; MALE; MIDDLE AGED; MISSENSE MUTATION; PATHOLOGY; PHENOTYPE; REGRESSION ANALYSIS; SEX DIFFERENCE; VARIABLE NUMBER OF TANDEM REPEAT;

ADOLESCENT; ADULT; AGED; ALPHA-GALACTOSIDASE; CARDIOMYOPATHY, HYPERTROPHIC; CASE-CONTROL STUDIES; CHILD; EXONS; FABRY DISEASE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GERMANY; HAPLOTYPES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INTRONS; MALE; MIDDLE AGED; MINISATELLITE REPEATS; MUTATION, MISSENSE; MYOCARDIUM; NITRIC OXIDE SYNTHASE TYPE III; PHENOTYPE; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; SEX FACTORS; YOUNG ADULT;

EID: 84855601509     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-008-0920-z     Document Type: Article

References (15)

1. Altarescu G, Moore DF, Pursely R, et al (2001) Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke 32:1559-1562.
2. Casas JP, Cavalleri GL, Bautista LE, Smeeth L, Humphries SE, Hingnorani AD (2006) Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGe review. Am J Epidemiol 164:921-935. doi:10.1093/aje/kwj302.
3. Charles IG, Scorer CA, Moro MA (1996) Expression of human nitric oxide synthase isoforms. Methods Enzymol 268:449-460. doi:10.1016/S0076-6879 (96) 68047-1.
4. Chimenti C, Hamdani N, Boontje NM, et al (2008) Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease. Am J Pathol 172:1482-1490. doi:10.2353/ajpath.2008.070576.
5. Desnick R, Ioannou Y, Eng CM (2001). Alpha-galactosidase a deficiency: Fabry disease. In: Valle D, ed. The Metabolic and Molecular Bases of Inherited Storage Diseases, 8th ed. New York: McGraw-Hill, 3733-3774.
6. Elleder M, Bradova V, Smid V, et al (1990) Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease: report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 417:449-455. doi:10.1007/BF01606034.
7. Forte P, Kneale BJ, Ritter JM (1998) Evidence for a difference in nitric oxide biosynthesis between healthy women and men. Hypertension 32:730-734.
8. Heltianu C, Costache G, Azibi K, Poenaru L, Simionescu M (2002) Endothelial nitric oxide synthase gene polymorphisms in Fabry's disease. Clin Genet 61:423-429. doi:10.1034/j.1399-0004.2002.610605.x.
9. MacDermot KD, Holmes A, Miners AH (2001) Natural history of Fabry disease in affected males and obligate carriers. J Inherit Metab Dis 24(Supplement 2):13-14. doi:10.1023/A:1012447102358.
10. Marroni AS, Metzger IF, Souza-Costa DC, et al (2005) Consistent interethnic differences in the distribution of clinically relevant endothelial nitric oxide synthase genetic polymorphisms. Nitric Oxide 12:177-182. doi:10.1016/j.niox.2005.02.002.
11. Persu A, Stoenoiu M, Messiaen T (2002) Modifier effect of eNOS in autosomal dominant polycystic kidney disease. Hum Mol Genet 11:229-241. doi:10.1093/hmg/11.3.229.
12. Senthil D, Raveendran M, Shen YH, et al (2005). Genotypedependant expression of endothelial nitric oxide synthase (eNOS) and its regulatory proteins in cultured endothelial cells. DNA Cell Biol 24:218-224. doi:10.1089/dna.2005. 24.218.
13. Tanus-Santos JE, Desai M, Flockhart DA (2001) Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics 11:719-725. doi:10.1097/00008571-200111000-00011.
14. Veldman BA, Spiering W, Doevendans PA, et al (2002) The Glu298Asp polymorphism of the NOS3 gene as a determinant of the baseline production of nitric oxide. J Hypertens 20:2023-2027. doi:10.1097/00004872-200210000-00022.
15. Wang J, Dudley D, Wang XL (2002) Haplotype-specific effects on endothelial NO synthase promoter efficiency: modifiable by cigarette smoking. Arterioscler Thromb Vasc Biol 22:e1-4. doi:10.1161/01. ATV.0000016248.51577.1F.